Innovation adoption in substance abuse treatment

Exposure, trialability, and the Clinical Trials Network

Lori J. Ducharme, Hannah K. Knudsen, Paul M. Roman, J Aaron Johnson

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Researchers and policymakers are increasingly focusing on factors that facilitate or impede the diffusion of evidence-based treatment techniques into routine clinical practice. One potentially fruitful avenue of research is the influence of involvement in research networks as a predictor of organizational innovation. The Clinical Trials Network (CTN) is examining a number of behavioral and pharmacological treatment techniques in controlled multisite studies. Using data from participating CTN treatment programs and large samples of programs outside the CTN, these analyses examine the influence of exposure to clinical trials on the subsequent adoption of buprenorphine and voucher-based motivational incentives. The analyses show that, controlling for a variety of organizational characteristics, direct exposure to buprenorphine clinical trials in the CTN significantly increased the odds of subsequent adoption. By contrast, the adoption of motivational incentives was entirely explained by organizational characteristics. The findings suggest that adoption of treatment innovations is a function of exposure, organizational resources, nature of innovations, and stage of the diffusion process.

Original languageEnglish (US)
Pages (from-to)321-329
Number of pages9
JournalJournal of Substance Abuse Treatment
Volume32
Issue number4
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Substance-Related Disorders
Clinical Trials
Buprenorphine
Motivation
Diffusion of Innovation
Organizational Innovation
Research
Research Personnel
Pharmacology

Keywords

  • Addiction treatment
  • Buprenorphine
  • Contingency management
  • Innovation
  • Motivational incentives

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Innovation adoption in substance abuse treatment : Exposure, trialability, and the Clinical Trials Network. / Ducharme, Lori J.; Knudsen, Hannah K.; Roman, Paul M.; Johnson, J Aaron.

In: Journal of Substance Abuse Treatment, Vol. 32, No. 4, 01.06.2007, p. 321-329.

Research output: Contribution to journalArticle

@article{8f67704a1ec143f4a67486e0987b18fd,
title = "Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network",
abstract = "Researchers and policymakers are increasingly focusing on factors that facilitate or impede the diffusion of evidence-based treatment techniques into routine clinical practice. One potentially fruitful avenue of research is the influence of involvement in research networks as a predictor of organizational innovation. The Clinical Trials Network (CTN) is examining a number of behavioral and pharmacological treatment techniques in controlled multisite studies. Using data from participating CTN treatment programs and large samples of programs outside the CTN, these analyses examine the influence of exposure to clinical trials on the subsequent adoption of buprenorphine and voucher-based motivational incentives. The analyses show that, controlling for a variety of organizational characteristics, direct exposure to buprenorphine clinical trials in the CTN significantly increased the odds of subsequent adoption. By contrast, the adoption of motivational incentives was entirely explained by organizational characteristics. The findings suggest that adoption of treatment innovations is a function of exposure, organizational resources, nature of innovations, and stage of the diffusion process.",
keywords = "Addiction treatment, Buprenorphine, Contingency management, Innovation, Motivational incentives",
author = "Ducharme, {Lori J.} and Knudsen, {Hannah K.} and Roman, {Paul M.} and Johnson, {J Aaron}",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.jsat.2006.05.021",
language = "English (US)",
volume = "32",
pages = "321--329",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Innovation adoption in substance abuse treatment

T2 - Exposure, trialability, and the Clinical Trials Network

AU - Ducharme, Lori J.

AU - Knudsen, Hannah K.

AU - Roman, Paul M.

AU - Johnson, J Aaron

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Researchers and policymakers are increasingly focusing on factors that facilitate or impede the diffusion of evidence-based treatment techniques into routine clinical practice. One potentially fruitful avenue of research is the influence of involvement in research networks as a predictor of organizational innovation. The Clinical Trials Network (CTN) is examining a number of behavioral and pharmacological treatment techniques in controlled multisite studies. Using data from participating CTN treatment programs and large samples of programs outside the CTN, these analyses examine the influence of exposure to clinical trials on the subsequent adoption of buprenorphine and voucher-based motivational incentives. The analyses show that, controlling for a variety of organizational characteristics, direct exposure to buprenorphine clinical trials in the CTN significantly increased the odds of subsequent adoption. By contrast, the adoption of motivational incentives was entirely explained by organizational characteristics. The findings suggest that adoption of treatment innovations is a function of exposure, organizational resources, nature of innovations, and stage of the diffusion process.

AB - Researchers and policymakers are increasingly focusing on factors that facilitate or impede the diffusion of evidence-based treatment techniques into routine clinical practice. One potentially fruitful avenue of research is the influence of involvement in research networks as a predictor of organizational innovation. The Clinical Trials Network (CTN) is examining a number of behavioral and pharmacological treatment techniques in controlled multisite studies. Using data from participating CTN treatment programs and large samples of programs outside the CTN, these analyses examine the influence of exposure to clinical trials on the subsequent adoption of buprenorphine and voucher-based motivational incentives. The analyses show that, controlling for a variety of organizational characteristics, direct exposure to buprenorphine clinical trials in the CTN significantly increased the odds of subsequent adoption. By contrast, the adoption of motivational incentives was entirely explained by organizational characteristics. The findings suggest that adoption of treatment innovations is a function of exposure, organizational resources, nature of innovations, and stage of the diffusion process.

KW - Addiction treatment

KW - Buprenorphine

KW - Contingency management

KW - Innovation

KW - Motivational incentives

UR - http://www.scopus.com/inward/record.url?scp=34247546059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247546059&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2006.05.021

DO - 10.1016/j.jsat.2006.05.021

M3 - Article

VL - 32

SP - 321

EP - 329

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 4

ER -